Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

H-7

PKC inhibitor
 
BML-EI148-0010 10 mg 86.00 USD
 
BML-EI148-0050 50 mg 344.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-270-016

Inhibits PKA (Ki=3.0μM), PKG (Ki=5.8μM), MLCK (Ki=97μM) and PKC (Ki=6μM). Also inhibits myosin light chain kinase. Induces apoptotic DNA fragmentation and cell death. Inhibits telomerase activity in treated NPC-076 cells. Cell permeable.

Product Specification

Alternative Name:(±)-1-(5-Isoquinolinesulfonyl)-2-methylpiperazine . 2HCl
 
Formula:C14H17N3O2S . 2 HCl
 
MW:364.3
 
CAS:108930-17-2
 
Purity:≥98% (TLC)
 
Appearance:White to light yellow solid.
 
MeltingPoint:219-222°C
 
Solubility:Soluble in water (50mg/ml), 100% ethanol or DMSO.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Store, as supplied, at 0-4°C for up to 1 year. Store solutions at -20°C for up to 3 months.
 
Handling:Protect from light.
 
ALX-270-016
Please mouse over
ALX-270-016

Product Literature References

Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture: W.C. Ku, et al.; Biochem. Biophys. Res. Commun. 241, 730 (1997), Abstract;
Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity: R.A. Engh, et al.; J. Biol. Chem. 271, 26157 (1996), Abstract; Full Text
Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C: W.D. Jarvis, et al.; Cancer Res. 54, 1707 (1994), Abstract;
Cellular interactions with the extracellular matrix are coupled to diverse transmembrane signaling pathways.: C. Gimond and M. Aumailley; Exp. Cell Res. 203, 365 (1992), Abstract;
Modulation of neutrophil superoxide generation by inhibitors of protein kinase C, calmodulin, diacylglycerol and myosin light chain kinases, and peptidyl prolyl cis-trans isomerase: H. Bergstrand, et al.; J. Pharmacol. Exp. Ther. 263, 1334 (1992), Abstract;
The structure and biological activities of the widely used protein kinase inhibitor, H7, differ depending on the commercial source: J. Quick, et al.; BBRC 187, 657 (1992), Abstract;
Blockade of the spinal excitatory effect of cAMP on the startle reflex by intrathecal administration of the isoquinoline sulfonamide H-8: comparison to the protein kinase C inhibitor H-7: N.M. Boulis & M. Davis; Brain Res. 525, 198 (1990), Abstract;
Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C: I. Takahashi, et al.; J. Pharmacol. Exp. Ther. 255, 1218 (1990), Abstract;
Stimulus-dependent inhibition of platelet aggregation by the protein kinase C inhibitors polymyxin B, H-7 and staurosporine: C. Schächtele, et al.; BBRC 151, 542 (1988), Abstract;
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine (H-7) is a selective inhibitor of protein kinase C in rabbit platelets: S. Kawamoto & H. Hidaka; BBRC 125, 258 (1984), Abstract;
Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.: H. Hidaka et al.; Biochemistry 23, 5036 (1984), Abstract;

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,